The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis (MStep)

April 25, 2017 updated by: Nancy Mayo, McGill University

Despite the benefits of exercise and physical activity people with Multiple Sclerosis (MS) are relatively inactive. Physical activity is important for persons with disabilities to maintain physical function. A lack of physical activity can contribute to heart disease, osteoporosis, obesity, and diabetes. At the moment, the best way for people with MS to exercise and be physical activity is unknown. People with MS report not knowing what to do. This is a barrier to exercise.

The global aim of this study is to contribute evidence for the role of targeted exercise in altering MS outcomes over time. The design is a randomized controlled trial (RCT). The primary research question is to what extent does an MS Tailored Exercise Program (MSTEP) result in greater improvements in exercise capacity and related outcomes in comparison to a program based on general guidelines for exercise among people with MS who are sedentary and wish to engage in exercise as part of MS self-management. The primary outcome for this question is exercise capacity measured using cycle ergometry. However exercise efficiency, functional ambulation, strength, components of quality of life including frequency and intensity of fatigue symptoms, mood, global physical function, health perception, and illness intrusiveness, will also be measured as components of a global response outcome. The first confirmatory hypothesis is that MSTEP will result in a greater proportion of people making clinically relevant gains (at least 10% change) in exercise capacity than with general guidelines after 12 months of intervention; a secondary hypothesis is that, while there may be some decline in exercise capacity among individuals from end of intervention to follow-up one year later, the decline will be greater in the general guideline group augmenting the difference between groups in the proportion making 10% change from study entry to 24 months. In other words, gains will be maintained more for the MSTEP group over the general guideline group.

An exploratory hypothesis is that more of the targeted outcomes will improve with the MSTEP program than the general guideline approach. An explanatory hypothesis is that these gains will be accompanied by reports of greater exercise enjoyment and exercise self-efficacy (confidence) with the MSTEP program than with the general guideline program leading to more consistent exercise engagement and improved long-term adherence.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The proposal is for an assessor-blind, parallel-group, stratified, randomized controlled trial. Potential participants will be identified from the population of persons enrolled in 3 MS clinics in the Montreal area and in 3 clinics in Toronto. All persons who are known to be ambulatory and not to have co-morbidity preventing exercise engagement or capacity to consent will be informed of the study in writing and will be invited for an assessment to determine eligibility for entry into the trial. Those consenting will be randomly assigned to either the MSTEP program or the general exercise guideline program. The intervention period will be one year with follow-up to a second year.

The investigators are targeting a sample size of 120 per group (total 240), which would be sufficient to detect RR of > 1.5 with 80% power. Sample size estimated using pc-size software. The sample size takes into account that drop-outs will inflate the variance of outcomes as multiple imputation will be used to deal with missing data.

The main analysis will be logistic regression to test the main hypothesis related to the superiority of the MSTEP program based on a greater proportion of people making a clinically relevant gain in exercise capacity at 1 year. A secondary outcome will be the differences in proportions at 2 years also using logistic regression. The analysis will be based on intention-to-treat and all persons will be analysed in the groups to which they were randomized.

A secondary analysis will estimate the impact of exercise on the other relevant outcomes. For this approach, each outcome will be converted to a binary response variable based on published clinically meaningful changes and generalized estimating equations (GEE) will be used to test the rate of response in the MSTEP program to the rate of response in the general guideline approach. Multiple outcomes improves the efficiency of the study as the total number of data points is equivalent to the total n multiplied by the number of tests and reduced by the extent to which the outcomes are correlated. Highly correlated outcomes will make the effective sample size smaller than less strongly correlated outcomes. If there is a statistically significant effect of the intervention, then and only then, can the effects of the separate outcomes be interpreted as real.

The results of the trial will be used to develop guidelines for exercise for MS. The investigators are in the process of copyrighting the name of the program (MSTEP). Upon publication of the findings, the description of content will be made available at no cost. If proven effective, a training guide for professionals and patients will be produced most likely taking advantage of the end-of-grant Knowledge Translation (KT) Supplement. Note: The investigators have been funded by the KT supplement to produce a general guide for people with MS, entitled: Getting on with Your Life with MS. The knowledge generated can be used by people with MS and health professional to promote exercise engagement.

Study Type

Interventional

Enrollment (Anticipated)

240

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada
        • St. Michael's Hospital
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Hospital
      • Toronto, Ontario, Canada
        • Toronto Rehabiliation institute
    • Quebec
      • Montreal, Quebec, Canada
        • CHUM
      • Montreal, Quebec, Canada
        • Muhc - Mnh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • be community dwelling individuals aged 19 -65 who have been diagnosed after 1994 with MS or CIS;
  • be able to speak and read English or French;
  • be capable of walking 100 meters without a walking aid (EDSS ≤ 5.5), even if they do use an aid for daily activities.

Exclusion Criteria:

  • have an additional illness that restricts their function; and/or
  • had suffered at least one relapse during the past 30 days (as defined by Polman) as this may affect physical activity/exercise participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MSTEP
The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
Other: MStep
Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
Active Comparator: General guideline approach
The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
Other: General guideline approach
Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
oxygen consumption
Time Frame: 3 timepoints: baseline, at 12 monts, at 24 months
VO2peak will be determined using an incremental graded cycle ergometer test. Greater oxygen consumption implies in better exercise capacity
3 timepoints: baseline, at 12 monts, at 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
muscle strength measured with Biodex
Time Frame: 3 timepoints: Baseline, at 12 months, at 24 months
Greater values imply greater muscle strength
3 timepoints: Baseline, at 12 months, at 24 months
6 Minute Walk test (6MWT)
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Distance walked will be measured with the 6-Minute Walk Test. Greater values imply that a longer distance was covered within 6 minutes
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Anaerobic leg power
Time Frame: 1 timepoint: baseline
Greater value indicate greater anaerobic leg power
1 timepoint: baseline
Patient Determined Disease Steps (PDDS)
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Patient Determined Disease Steps (PDDS) is a scale focusing mainly on how well someone walk. It ranges from mild symptoms that do not affect physical activity to inability to sit in a wheel chair for more than 1 hour.
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Change in fatigue levels
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Fatigue will be measured with a single item question asking them the number of days that they felt certain levels of fatigue.
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Rand 36
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Health status will be measured with the Rand36 Health Status Survey. The Rand36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
EQ-5D
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
The respondent is asked to indicate his/her health state in each of 5 dimensions. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Patient generated Index
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Participants will be asked to identify 5 most important areas of their life that are affected by multiple sclerosis. A second step will be to score how much affected these identified areas were over the past MONTH, in a scale from 1 to 10.
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Exercise Self-Efficacy Scale
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
This will be measured by the Exercise Self-Efficacy Scale, in which participants are asked how certain they are that they can get to perform an exercise routine regularly (three or more times a week). The scale ranges from 0 (not confident) to 100 (highly confident).
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Change in perception about exercise benefits and exercise barrier
Time Frame: 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months

It will be measured with a self-reported questionnaire. For the exercise benefits, the scale range as "strongly disagree, disagree, agree, strongly agree".

For the exercise barriers the scale range as "sometimes a barrier", "often a barrier"
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Modified Canadian Aerobic Fitness test
Time Frame: 3 timepoints: 3 month, 6 month and 18 month

mCAFT is a graded step test and can predict VO2peak using a regression equation recently published. Thus, we are confident that we will get usable data for each person and as we are looking for a proportion of people who change over time, persons who do not achieve a peak and have low values on the mCAFT will have a very low value for exercise capacity.

Greater steps cadence imply on greater oxygen cost
3 timepoints: 3 month, 6 month and 18 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

McGill University

Investigators

  • Principal Investigator: Nancy E Mayo, PhD, McGill University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2012

Primary Completion (Anticipated)

December 1, 2017

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

May 22, 2012

First Submitted That Met QC Criteria

June 2, 2012

First Posted (Estimate)

June 5, 2012

Study Record Updates

Last Update Posted (Actual)

April 26, 2017

Last Update Submitted That Met QC Criteria

April 25, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIHR258309

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on MStep

  • Seattle Children's Hospital
    Eunice Kennedy Shriver National Institute of Child Health and Human Development...
    Active, not recruiting
    Mobile Subthreshold Exercise Program for Concussion--R01 (MSTEP-R01)
    Brain Injuries, Traumatic | Post-Concussion Syndrome | Concussion, Mild | Persistent Post Traumatic Headache | Concussion, Brain | Post-Concussive Syndrome, Chronic
    United States

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe